IL140761A0 - Sustained release pharmaceutical preparation - Google Patents

Sustained release pharmaceutical preparation

Info

Publication number
IL140761A0
IL140761A0 IL14076199A IL14076199A IL140761A0 IL 140761 A0 IL140761 A0 IL 140761A0 IL 14076199 A IL14076199 A IL 14076199A IL 14076199 A IL14076199 A IL 14076199A IL 140761 A0 IL140761 A0 IL 140761A0
Authority
IL
Israel
Prior art keywords
coating
sustained release
active ingredient
pharmaceutical preparation
release pharmaceutical
Prior art date
Application number
IL14076199A
Other languages
English (en)
Original Assignee
Cascade Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/111,188 external-priority patent/US5968554A/en
Application filed by Cascade Dev Inc filed Critical Cascade Dev Inc
Publication of IL140761A0 publication Critical patent/IL140761A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14076199A 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation IL140761A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/111,188 US5968554A (en) 1998-07-07 1998-07-07 Sustained release pharmaceutical preparation
US09/338,716 US6312728B1 (en) 1998-07-07 1999-06-23 Sustained release pharmaceutical preparation
PCT/US1999/014204 WO2000001369A1 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Publications (1)

Publication Number Publication Date
IL140761A0 true IL140761A0 (en) 2002-02-10

Family

ID=26808709

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14076199A IL140761A0 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Country Status (10)

Country Link
US (1) US6312728B1 (https=)
EP (1) EP1094790B9 (https=)
JP (1) JP2003524592A (https=)
AT (1) ATE274344T1 (https=)
AU (1) AU5084299A (https=)
CA (1) CA2337046C (https=)
DE (1) DE69919713T2 (https=)
ES (1) ES2226412T3 (https=)
IL (1) IL140761A0 (https=)
WO (1) WO2000001369A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20040043067A1 (en) * 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
WO2005030179A1 (en) * 2003-09-29 2005-04-07 Cj Corporation Sustained-release formulations
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
WO2005117697A2 (en) * 2004-05-28 2005-12-15 Narayanan Ramasubramanian Unified indigestion package and process for patient compliance with prescribed medication regimen
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
AU2007214487A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
CA2687130C (en) * 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CA3165418A1 (en) 2019-12-27 2021-07-01 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
US20230190831A1 (en) 2020-04-17 2023-06-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
TW202228653A (zh) 2020-09-18 2022-08-01 美商艾弗洛生物科技股份有限公司 細菌之固體劑型
EP4236973A1 (en) 2020-10-29 2023-09-06 Evelo Biosciences, Inc. Compositions comprising spirulina components
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細胞外小胞調製物
US20240226188A9 (en) 2020-12-22 2024-07-11 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
US20240423924A1 (en) 2021-01-26 2024-12-26 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
WO2022182707A1 (en) 2021-02-26 2022-09-01 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
TW202304415A (zh) 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
US20250114411A1 (en) 2021-09-24 2025-04-10 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023114296A2 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle preparations
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
US5368861A (en) * 1989-10-26 1994-11-29 Nippon Shinyaku Co., Ltd. Gastric preparation with sustained release
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
EP1094790B9 (en) 2005-05-04
ATE274344T1 (de) 2004-09-15
CA2337046A1 (en) 2000-01-13
EP1094790B1 (en) 2004-08-25
US6312728B1 (en) 2001-11-06
DE69919713D1 (de) 2004-09-30
CA2337046C (en) 2005-08-16
AU5084299A (en) 2000-01-24
EP1094790A1 (en) 2001-05-02
ES2226412T3 (es) 2005-03-16
DE69919713T2 (de) 2005-09-22
EP1094790A4 (en) 2003-03-12
JP2003524592A (ja) 2003-08-19
WO2000001369A1 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
IL140761A0 (en) Sustained release pharmaceutical preparation
AU1227899A (en) Osmotic medicament releasing system
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
EP1818029A3 (en) Sequential drug delivery systems
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
IL165786A0 (en) Ibuprofen suspension
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
IL150528A0 (en) Ibuprofen containing active agent preparation
AP2003002763A0 (en) Controlled release formulations for oral administration
GB2328872B (en) Method for preparing pharmaceutical formulations
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
UA89349C2 (uk) Таблетка без покриття, яка містить оланзапін, та спосіб її одержання
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
GEP20043377B (en) Pharmaceutical Complex
EP0815851A3 (en) Method of reducing irritativeness of surface active agents and aqueous compositions with reduced irritativeness
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.